JOP20210140A1 - معالجة متلازمة الحذف 22q11.2 بكانابيديول - Google Patents
معالجة متلازمة الحذف 22q11.2 بكانابيديولInfo
- Publication number
- JOP20210140A1 JOP20210140A1 JOP/2021/0140A JOP20210140A JOP20210140A1 JO P20210140 A1 JOP20210140 A1 JO P20210140A1 JO P20210140 A JOP20210140 A JO P20210140A JO P20210140 A1 JOP20210140 A1 JO P20210140A1
- Authority
- JO
- Jordan
- Prior art keywords
- cannabidiol
- deletion syndrome
- treatment
- subject
- behavioral symptoms
- Prior art date
Links
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 title abstract 3
- 208000000398 DiGeorge Syndrome Diseases 0.000 title abstract 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 3
- 229950011318 cannabidiol Drugs 0.000 title abstract 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 3
- 208000013404 behavioral symptom Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/035—Halogenated hydrocarbons having aliphatic unsaturation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
غير متوفر
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779591P | 2018-12-14 | 2018-12-14 | |
| US201962895279P | 2019-09-03 | 2019-09-03 | |
| PCT/IB2019/060735 WO2020121260A1 (en) | 2018-12-14 | 2019-12-12 | Treatment of 22q11.2 deletion syndrome with cannabidiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210140A1 true JOP20210140A1 (ar) | 2023-01-30 |
Family
ID=69137939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0140A JOP20210140A1 (ar) | 2018-12-14 | 2019-12-12 | معالجة متلازمة الحذف 22q11.2 بكانابيديول |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11458109B2 (ar) |
| EP (1) | EP3893858A1 (ar) |
| KR (1) | KR20210104084A (ar) |
| AU (1) | AU2019396750A1 (ar) |
| BR (1) | BR112021011279A2 (ar) |
| CA (1) | CA3122735A1 (ar) |
| IL (1) | IL283929A (ar) |
| JO (1) | JOP20210140A1 (ar) |
| MX (1) | MX2021007076A (ar) |
| WO (1) | WO2020121260A1 (ar) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058102T2 (hu) | 2017-09-28 | 2022-07-28 | Zynerba Pharmaceuticals Inc | Fragilis X szindróma és autizmus kezelése kannabidiollal |
| EP3893858A1 (en) * | 2018-12-14 | 2021-10-20 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20020333A0 (fi) | 2002-02-20 | 2002-02-20 | Tomi Jaervinen | Metyloidun syklodekstriinin uudet kompleksit |
| CA2760460C (en) | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| CN105848646B (zh) | 2013-10-29 | 2019-10-22 | 艾克制药有限公司 | 包含大麻二酚的压制片剂、其制造方法以及此类片剂在口服治疗精神病症或焦虑症中的用途 |
| JP6659933B2 (ja) | 2014-05-29 | 2020-03-04 | フレッシュ・カット・ディベロップメント・エル・エル・シー | 安定なカンナビノイド製剤 |
| US20160271252A1 (en) | 2014-05-29 | 2016-09-22 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| US20170224634A1 (en) | 2014-05-29 | 2017-08-10 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| AU2015279612A1 (en) | 2014-06-27 | 2017-02-02 | Kenton L. Crowley | Buccal and sublingual cannabinoid formulations and method of making the same |
| WO2016004121A1 (en) | 2014-07-01 | 2016-01-07 | MJAR Holdings, LLC | High cannabidiol cannabis strains |
| EP3209312A1 (en) | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| US10716766B2 (en) | 2015-03-02 | 2020-07-21 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
| WO2017068349A1 (en) | 2015-10-23 | 2017-04-27 | E-Therapeutics Plc | Cannabinoid for use in immunotherapy |
| WO2017151980A1 (en) | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| US20190060300A1 (en) | 2016-03-04 | 2019-02-28 | Sharon Anavi-Goffer | Self-Emulsifying Compositions of CB2 Receptor Modulators |
| IL307857A (en) | 2016-03-16 | 2023-12-01 | Buzzelet Development And Technologies Ltd | Cannobinoid compounds are rich in terpenes |
| TWI790204B (zh) | 2016-06-02 | 2023-01-21 | 加拿大商阿爾宙斯製藥有限公司 | 鼻用大麻素組成物 |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| EP3893858A1 (en) * | 2018-12-14 | 2021-10-20 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
-
2019
- 2019-12-12 EP EP19832440.2A patent/EP3893858A1/en active Pending
- 2019-12-12 JO JOP/2021/0140A patent/JOP20210140A1/ar unknown
- 2019-12-12 MX MX2021007076A patent/MX2021007076A/es unknown
- 2019-12-12 BR BR112021011279-0A patent/BR112021011279A2/pt unknown
- 2019-12-12 CA CA3122735A patent/CA3122735A1/en active Pending
- 2019-12-12 AU AU2019396750A patent/AU2019396750A1/en active Pending
- 2019-12-12 US US16/712,066 patent/US11458109B2/en active Active
- 2019-12-12 WO PCT/IB2019/060735 patent/WO2020121260A1/en unknown
- 2019-12-12 KR KR1020217021748A patent/KR20210104084A/ko unknown
-
2021
- 2021-06-13 IL IL283929A patent/IL283929A/en unknown
-
2022
- 2022-09-30 US US17/957,932 patent/US20230024756A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11458109B2 (en) | 2022-10-04 |
| US20230024756A1 (en) | 2023-01-26 |
| IL283929A (en) | 2021-07-29 |
| MX2021007076A (es) | 2021-08-11 |
| EP3893858A1 (en) | 2021-10-20 |
| US20200188324A1 (en) | 2020-06-18 |
| BR112021011279A2 (pt) | 2021-08-31 |
| CA3122735A1 (en) | 2020-06-18 |
| KR20210104084A (ko) | 2021-08-24 |
| WO2020121260A1 (en) | 2020-06-18 |
| AU2019396750A1 (en) | 2021-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012424A (es) | Tratamiento del sindrome del cromosoma x fragil con canabidiol. | |
| JOP20210140A1 (ar) | معالجة متلازمة الحذف 22q11.2 بكانابيديول | |
| EA201590849A1 (ru) | Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови | |
| GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
| MX2022003193A (es) | Tratamiento de encefalopatia asociada al gen syngap1. | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| MX2020013004A (es) | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. | |
| TN2019000019A1 (en) | Treatment and prevention of sleep disorders | |
| MX2017004580A (es) | Combinaciones de auristatina sinergica. | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| EA202193111A1 (ru) | Композиции и способы для лечения рака | |
| BR112018014467A2 (pt) | tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças | |
| BR112022007523A2 (pt) | Limpeza e despoluição de fibras originadas a partir de pontas de cigarro usadas pelo contato com um fluido supercrítico e reciclagem das fibras despoluídas | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| JOP20220310A1 (ar) | علاج اضطراب طيف التوحد بكانابيديول | |
| MX2019012659A (es) | Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido. | |
| BR112018069174A2 (pt) | tratamento de prurido urêmico | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| CL2021000743A1 (es) | Métodos para tratar trastornos mieloproliferativos | |
| EP4233842A3 (en) | Avexitide for the treatment of hyperinsulinemic hypoglycemia |